University of Patras
Φαρμακοκινητική και φαρμακοδυναμική μελέτη του αντικαρκινικού συνθετικού πεπτιδίου PCK3145 και PEG-PCK3145 σε ζώα
Abstract
dc:descriptionProtein PSP94 (also known as β-micrososinoprotein, with a molecular weight of 14 kDa) plays an inhibitory role in carcinogenesis, induces tumor cell apoptosis and reduces tumor growth both in vitro and in vivo (Garde et al., 1999; Shukeir et al., 1999; al., 2003). Research groups have attempted to study the action of PSP94 and elucidate the pharmacophore sequence that has this specific protective anti-cancer activity. After studying 12 amino acid sequences of PSP94, it was found that the 15-peptide from the 31st to the 45th amino acid, with code named PCK3145, has the best anti-antiogenetic and anti-metastatic activity in in vitro and in vivo cancer models (Shukeir et al., 2004). The mechanism of action of PCK3145 is not fully known but has been found to inhibit the secretion of metalloproteinase-9 (MMP-9) through rapid phosphorylation of ERK kinase as well as its subsequent binding to the cell surface leading to anti-metastatic activity (Annabi, Bouzeghrane, et al., 2006). It also inhibits the expression of vascular endothelial growth factor (VEGF) signaling through ERK phosphorylation, which reflects its anti-antiogenetic activity (Lamy et al., 2006).However, the low in vivo stability of PCK3145 as well as its rapid rate of clearance severely limit its clinical use in humans (Hawkins et al., 2005).The present doctoral thesis aims to investigate the pharmacokinetic and pharmacodynamic profile of PCK3145 by conjugating with polyethylene glycol 20 (PEG 20). Biochemical modification of molecules with polyethylene glycol is known to alter pharmacokinetics, prolonging the half-life and delaying the clearance of many biologically active compounds (Harris, Martin and Modi, 2001; Haubner et al., 2001; Dennis et al., 2002). LC-MS / MS, UHPLC-UV and ELISA analytical methods were developed and validated to quantify PCK3145 and PEG-PCK3145 in mouse plasma. Specifically, the LC-MS / MS method was used to determine the parent PCK3145 with a linearity range of 0.125 to 4.0 µg/mL and accuracy and precision within the acceptable range (15% of the actual value for the quality control samples and 20 % for the lowest concentration level). The UHPLC-UV method with a calibration curve range of 0.05 to 2.0 mg/mL with excellent accuracy and precision within the acceptable range (15% of the actual value for the quality control samples) was used to determine PEG-PCK3145 in mouse plasma. Additionally, for the determination of PCK3145 after conjugation with polyethylene glycol, the pegylated peptide calibration curve from 1.76 to 56.3 ng / mL was applied.The above methods were successfully employed to study the stability of peptides in mice plasma under different storage conditions. The findings of the stability study indicate that after one week of storage at 4-8 °C, three repeated freeze-thaw cycles and storage for 6 months at -20 ° C remained stable. In addition, the proteolytic stability of the peptides in whole blood and mouse plasma was studied and as a result they remain intact after 24 hours of incubation at 37 °C (95% of PCK3145 and 92% of PEG). The pharmacokinetic profile of PCK3145 was studied before and after conjugating to polyethylene glycol 20, in two groups of twelve male SCID mice, after administration of 100 µg/kg PCK3145 and 1000 µg/kg PEG-PCK3145 (equal to 75 µg/kg PCK3145) intraperitoneally. The results of the pharmacokinetic study show that the half-life before and after pegylation was 9.25 and 11.55 minutes (p=0.074), the clearance was 0.088 and 0.023 mL/min (p=0.081) and the volume of distribution was 1.17 and 0.37 mL (p=0.067), respectively.Finally, the in vivo antitumor activity of PEG-PCK3145 was investigated following intraperitoneal administration to SCID mice with prostate tumor xenograft. The reduction of tumor size in SCID mice was measured after administration of 1000 µg/kg and 100 µg/kg PEG-PCK3145, 100 µg/kg PCK3145, 1000 µg/kg PEG20 (negative control) and 10 mg/kg docetaxel (positive control), once daily for 6 weeks. All the regimens showed a statistically significant decrease in tumor size compared to the negative control PEG20 (p<0.05). PEG-PCK3145 at a dose of 1000 µg/kg (corresponding to 75 µg/kg PCK3145) showed the same effect in terms of tumor reduction compared to 100 µg/kg of PCK3145. A clear dose-dependent response was observed for the PEG-PCK3145 as the lower dose of 100 µg/kg of PEG-PCK3145 (corresponding to 7.5 µg/kg PCK3145) was found to be less effective than the 1000 µg/kg of PEG-PCK3145 (p <0.05).In summary, the pegylation of PCK3145 gave a biologically active molecule, stable in storage conditions, as well as in enzymatic cleavage in whole blood and mouse plasma. PEG-PCK3145 has been shown to have an increased half-life and an apparent volume of distribution, with a reduced rate of clearance in mice relative to the parent peptide, but no statistical different in the pharmacokinetic parameters. In prostate tumor xenograft model, PEG-PCK3145 was found to be slightly more potent than the parent PCK3145 compared to equimolary. It would be of particular interest for future clinical use to optimize the pharmacokinetic parameters of the new anti-cancer synthetic peptide PCK3145, possibly by glycosylation or cyclization or the use of nanoparticles / liposomes.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Danika, Charikleia
- Δανίκα, Χαρίκλεια
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46943